PML mediates IFN-α–induced apoptosis in myeloma by regulating TRAIL induction
Open Access
- 1 February 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 105 (3) , 1280-1287
- https://doi.org/10.1182/blood-2004-04-1614
Abstract
Interferon (IFN) induces expression of proapoptotic genes and has been used in the clinical treatment of multiple myeloma. The promyelocytic leukemia (PML) gene is an IFN-induced target that encodes a tumor suppressor protein. PML protein is typically localized within discrete speckled nuclear structures termed PML nuclear bodies (NBs). Multiple myeloma cells demonstrate differential responses to IFN treatment, the mechanism of which is largely unknown. Herein, we show that growth inhibition effects of IFN-α in myeloma cells correlate with PML NBs and tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL) induction, whereas known IFN targets including signal transducer and activator of transcription-1 (STAT1), STAT3, p38, and Daxx cannot account for these differential responses. RNAi silencing of PML blocks IFN-α–induced apoptosis in myeloma cells and correspondingly down-regulates TRAIL expression. Similarly, stable expression of a dominant negative TRAIL receptor DR5 partially blocks IFN-induced cell death. These results demonstrate that PML and TRAIL play important roles in IFN-induced apoptosis and identify TRAIL as a novel downstream transcriptional target of PML. Identification of PML and PML NBs as effectors of IFN responses provides insights into mechanisms by which tumor cells exhibit resistance to this class of agents and may prove useful in assessing treatment regimens.Keywords
This publication has 43 references indexed in Scilit:
- c-Myb associates with PML in nuclear bodies in hematopoietic cellsExperimental Cell Research, 2004
- Opposing effects of PML and PML/RARα on STAT3 activityBlood, 2003
- An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growthOncogene, 2003
- Chk2 leaves the PML depotNature Cell Biology, 2002
- Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activitiesLeukemia, 2002
- Pondering the Promyelocytic Leukemia Protein (PML) Puzzle: Possible Functions for PML Nuclear BodiesMolecular and Cellular Biology, 2002
- Multiple MyelomaHematology-American Society Hematology Education Program, 2002
- Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasiasExpert Opinion on Investigational Drugs, 2001
- The Rac1/p38 Mitogen-activated Protein Kinase Pathway Is Required for Interferon α-dependent Transcriptional Activation but Not Serine Phosphorylation of Stat ProteinsJournal of Biological Chemistry, 2000
- Accommodating haploinsufficient tumour suppressor genes in Knudson's modelOncogene, 2000